Roche's giredestrant combo improves PFS in post-CDK4/6i ER+ breast cancer

Roche said on 1 October 2026 that giredestrant, its investigational oral selective estrogen receptor degrader, plus everolimus significantly improved progression-free survival over standard endocrine therapy plus everolimus in ER-positive, HER2-negative advanced breast cancer, with detailed results from the phase 3 evERA trial published in the New England Journal of Medicine ^[1][3]. The patients had already progressed on CDK4/6 inhibitors and endocrine therapy, the setting where options thin out and oncologists reach for the everolimus-plus-endocrine backbone ^[2].

What Roche has not released is the number that decides the regimen's commercial weight. Prognyx could not obtain these from public sources as of this briefing.

That gap matters more than usual, because evERA carried two co-primary endpoints: PFS in the ESR1-mutated subpopulation and PFS in the overall trial population ^[2]. Which one, or both, cleared the bar changes who the regimen can reach.

Why it matters

The approved oral SERD in this post-CDK4/6i space, camizestrant (ETCAMAH), is labeled for patients with an ESR1 mutation detected during aromatase inhibitor and CDK4/6 inhibitor therapy, in combination with a CDK4/6 inhibitor ^[4]. If giredestrant plus everolimus shows a convincing benefit in the overall population regardless of ESR1 status, it reaches the larger share of post-CDK4/6i patients that an ESR1m-restricted label does not cover. If the signal sits mainly in the ESR1-mutated subgroup, the two land closer to the same niche. The missing hazard ratio is the fact that separates those two scenarios.

The comparator Roche beat is itself the current fallback: everolimus added to endocrine therapy. A giredestrant-based regimen that improves on that backbone competes directly with how many clinics already treat this line ^[2].

Who is exposed

Camizestrant's position as the oral SERD for post-CDK4/6i ESR1-mutated disease, and the everolimus-plus-endocrine-therapy regimen that evERA used as its control ^[2][4]. Prognyx limits this to what the trial design directly supports.

What to watch next

• The full evERA dataset. The NEJM paper is dated 1 October 2026; the hazard ratio, median PFS by population and safety profile should surface in that text and at the next oncology congress ^[1][3].
• The ClinicalTrials.gov results posting. As of the 17 June 2026 registry record, evERA (NCT05306340) had no results posted and its primary completion date had already passed on 16 July 2025 ^[2]. That record predates the NEJM publication and should update.
• The broader program. A separate Roche umbrella trial (NCT04802759) testing giredestrant plus everolimus among other combinations was recruiting as of 3 September 2026, with primary completion set for 30 May 2029 ^[5].

The now-what

A competing development or BD team has three moves. Hold until the hazard ratio publishes, since the overall-population question is unresolved and the magnitude is unknown. Pressure-test an ESR1m-agnostic positioning now, on the chance evERA's overall-population endpoint cleared, which would widen the addressable population beyond camizestrant's label. Or revisit everolimus-combination assets, given that evERA supports the ER-plus-mTOR dual-target rationale in this line ^[1][2].

Verdict: moderate threat to the post-CDK4/6i oral SERD and everolimus-combination field, with the window to act open until Roche discloses the hazard ratio and the population split; until then the competitive magnitude stays unknowable.

What Prognyx could not verify

The magnitude of the PFS benefit and which co-primary population drove it ^[1][2]; any FDA or EMA filing for the giredestrant-everolimus combination, which no primary regulatory record in Prognyx's set confirms; and March 2026 trade headlines (Targeted Oncology, Seeking Alpha) describing a giredestrant phase 3 missing its PFS endpoint, which appear to reference a different trial (reported as persevERA, first-line versus letrozole) but which Prognyx could not open to confirm the trial identity.